In one study, no significant bacterial infections were documented in all investigated patients over the age of 14 with IRAK4 deficiency. This may mean that in later stages of life, IRAK4 inhibition could provide benefits against certain diseases while maintaining immunity.
The absence of bacterial infections in patients with IRAK4 deficiency, particularly those over 14 years old, implies that IRAK4 inhibition could be beneficial against specific diseases while maintaining immunity in later stages of life.